Brand and Other Names:Avapro
- Classes: ARBs
Dosing & Uses
Dosage Forms & Strengths
150 mg/day PO initially; may be increased to 300 mg/day PO
Hypovolemia: 75 mg/day PO initially
Nephropathy in Type 2 Diabetes
75-300 mg/day PO
Mild-to-severe renal impairment: Dosage adjustment not necessary unless patient is hypovolemic
Also given in combination with hydrochlorothiazide (Avalide)
Generally, adjust dosage monthly; adjust more aggressively in high-risk patients
Focal Segmental Glomerulosclerosis (Orphan)
Irbesartan and propagermanium: Orphan designation for treatment of focal segmental glomerulosclerosis
- Dimerix Bioscience Ltd; Level 2, 25 Flinders Lane; Melbourne
Dosage Forms & Strengths
<6 years: Safety and efficacy not established
6-12 years: 75 mg/day PO initially; not to exceed 150 mg/day
>12 years: 150 mg/day PO initially; may be increased to 300 mg/day PO
Serious - Use Alternative
Significant - Monitor Closely
Upper respiratory tract infection (URTI) (9%)
Orthostatic hypotension (5%)
Urticaria; angioedema (involving swelling of the face, lips, pharynx, or tongue); elevated liver function testresults; jaundice; hepatitis; hyperkalemia, and thrombocytopenia
Impaired renal function, including cases of renal failure, has been reported
Increased creatine phosphokinase (CPK) levels and rhabdomyolysis have been reported in patients receiving angiotensin-receptor blockers (ARBs)
Black Box Warnings
Discontinue as soon as possible when pregnancy is detected; drug affects renin-angiotensin system, causing oligohydramnios, which may result in fetal injury or death
Do not coadminister with aliskiren in patients with diabetes
Angioedema, volume-depletion, severe congestive heart failure (CHF), hepatic or renal impairment, hypertrophic cardiomyopathy, aortic or mitral valve stenosis, surgery or anesthesia
Discontinue immediately if patient is pregnant; risk of congenital malformations (see Contraindications and Black Box Warnings)
Use with caution in renal artery stenosis; avoid in bilateral renal artery stenosis
Risk of hypotension or hyperkalemia
Dual blockade of the renin-angiotensin system with ARBs, angiotensin-converting enzyme (ACE) inhibitors, or aliskiren is associated with increased risk of hypotension, hyperkalemia, and altered renal function (including acute renal failure) in comparison with monotherapy
Risk of heart failure-related morbidity; concomitant treatment with ACE inhibitors and beta-adrenergic agents is not recommended
Pregnancy & Lactation
Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D
Lactation: Potential harm to nursing infant; discontinue drug, or do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Angiotensin II receptor blocker; inhibits vasoconstrictor and aldosterone-secreting effects of angiotensin II
Onset: 1-2 hr (peak effect)
Duration: 24 hr
Peak plasma time: 1.5-2 hr
Protein bound: 90%
Vd: 53-93 L
Metabolized by hepatic CYP2C9 and minimally by CYP3A4
Metabolites: Irbesartan glucuronide conjugate (inactive)
Half-life: 11-15 hr
Renal clearance: 3-3.5 mL/min
Total body clearance: 157-176 mL/min
Excretion: Feces (80%), urine (20%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs